Imatinib was first developed as a treatment for chronic myeloid leukemia (CML) by inhibiting the intracellular tyrosine kinase termed the Abelson murine leukemia viral oncogene homolog (ABL) and the kinase breakpoint cluster region protein (BCR)-ABL fusion protein [6, 7]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.